Match tier Listed
Presence Current · Arkansas
Last published 2026
Sources OpenAlex · ORCID
Refreshed 2026-08-15

Megan R. Reed

Postdoc

Also affiliated: University of Minnesota (2015); Lutheran Medical Center (2024); California Lutheran University (2024); Virginia Commonwealth University (2016–2025); Hawkeye Community College (2015); Cancer Institute (WIA) (2025); Minnesota Orthopedic Sports Medicine Institute (2015); Twin Cities Orthopedics (2015); Magee-Womens Hospital (2018); Development Fund (2015); Medical Advanced Pain Specialists (2015); University of Applied Management Studies (2023); Winthrop Rockefeller Foundation (2025); Dermatology Specialists (2015); Arkansas Department of Agriculture (2026); Saint Louis University (2019)

Postdoc Researcher

15 h-index 47 pubs 725 cited

  • Humans
  • Receptors, Chimeric Antigen
  • G-Quadruplexes
  • Y-Family DNA Polymerases
  • DNA-Directed DNA Polymerase
  • Glioblastoma
  • Brain Neoplasms
  • Child
  • Neoplasms
  • Tumor Microenvironment
  • DNA Damage
  • Enzyme Inhibitors
  • Indoles
  • Cell Line, Tumor
  • Female

Biography and Research Information

OverviewAI-generated summary

Megan R. Reed's research focuses on cancer treatment strategies, particularly for glioblastoma. She has investigated the use of CAR-T therapies in solid tumors, exploring both their opportunities and challenges. Reed's work also includes the development of functional precision medicine pipelines that combine comparative transcriptomics and tumor organoid modeling to identify tailored treatment approaches for glioblastoma. Additionally, her research has explored the anti-glioblastoma activity of specific compounds like monensin and its analogs within organoid models. Her publications also touch upon broader areas of molecular biology, including the genetic encoding of photocaged amino acids for light-controlled protein activity and the development of genetically encoded biosensors for tracking the biosynthesis of semisynthetic antibiotics. Reed's scholarship metrics include an h-index of 15, with 47 total publications and 708 total citations.

Metrics

  • h-index: 15
  • Publications: 47
  • Citations: 725

Selected Publications

  • Abstract 6545: Characterizing ATF6 activation-driven mechanisms improving ICB efficacy (2026)
    Cancer Research DOI OpenAlex
  • Abstract 5189: Generating EZH2-inhibitor resistant CAR-T cells to sustain function for combination therapy (2026)
    Cancer Research DOI OpenAlex
  • 685 EZH2 inhibition impairs CD8+ CAR-T cell persistence (2025)
    Regular and Young Investigator Award Abstracts DOI OpenAlex
  • 691 ATF6 activation promotes ICB response in melanoma (2025)
    Regular and Young Investigator Award Abstracts DOI OpenAlex
  • Evaluation of the Activity of Monensin and Its Analogs for Modulation of Stem-like Cell Functionality in 2D and 3D Breast Cancer Models (2025)
    ACS Pharmacology & Translational Science 1 citation DOI OpenAlex
  • Monensin and Its Analogs Exhibit Activity Against Breast Cancer Stem-Like Cells in an Organoid Model (2025)
    bioRxiv (Cold Spring Harbor Laboratory) DOI OpenAlex
  • EZH2 loss during metabolic stress drives restoration of MHC class I machinery in melanoma (2025)
    iScience 1 citation DOI OpenAlex
  • Abstract 1488: DNA polymerase kappa slows replication fork speed by promoting fork reversal in glioblastoma (2025)
    Cancer Research 1 citation DOI OpenAlex
  • 1132 Enhancing melanoma therapy efficacy by protecting EZH2 activity in T cells (2024)
    Regular and Young Investigator Award Abstracts DOI OpenAlex
  • 538 ATF6 activation in melanoma promotes anti-tumor immunity and improves ICB therapy response (2024)
    Regular and Young Investigator Award Abstracts DOI OpenAlex
  • Abstract 1333 DNA polymerase kappa (Pol k) promotes replication gap suppression by preventing PrimPol mediated repriming and safeguards genomic stability in Glioblastoma Multiforme (GBM) (2024)
    Journal of Biological Chemistry DOI OpenAlex
  • Abstract 584: Synergistic action of ATF6 and EZH2 in sensing metabolic stress to boost anti-tumor immunity (2024)
    Cancer Research DOI OpenAlex
  • 536 EZH2 senses metabolic stress to restore MHC-I antigen presentation and ICB response in metastatic melanoma (2023)
    Regular and Young Investigator Award Abstracts DOI OpenAlex
  • Abstract LB041: EZH2 and ATF6 sense metabolic stress to balance MHC class I antigen presentation in melanoma (2023)
    Cancer Research DOI OpenAlex
  • CAR-T Therapies in Solid Tumors: Opportunities and Challenges (2023)
    Current Oncology Reports 191 citations DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

84 Collaborators 12 Institutions 3 Countries

Top Collaborators

View profile →
View profile →
View profile →
View profile →
View profile →
View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics